Minerva Capital Research Solutions

Shalby

NSE: SHALBYBSE: 540797
Compare with peers
₹ 121.30▲ 2.62 (+2.21%)28 Oct, 03:29 pm IST
Market cap
₹ 1,210 Cr.
P/E
33.7x
P/B
1.23x
52-week range
110.61 – 252.05
ROE
2%
ROCE
6%
Dividend yield
0%
Debt / equity
0.59
Sector
Healthcare Services
Industry
Hospital
Listed on
NSE, BSE

About

Shalby Limited is an India-based company, which operates multi-specialty hospital chains. The Company is engaged in the business of setting up and managing hospitals and medical diagnostic services. The Company’s Hospitals divisions include Multispecialty, Shalby Orthopedics Centre of Excellence (SOCE), Shalby Homecare, and Shalby Academy. Its Slaney Healthcare (Surgical & Pharma Products) divisions include Hosply (Hospital Supplies). Its Shalby MedTech divisions include Shalby Advanced Technologies Inc., USA (SAT), and Shalby Global Technologies PTE Ltd, Singapore (SGT). The Company offers a range of specialties, which include Bone and Joint, Cardiac Sciences, Cosmetic and Aesthetic, Dental Cosmetic and Implantology, Dermatology, Emergency Medicine, ENT Surgery, Gastro Sciences, General Medicine, General Surgery, Infertility and IVF, Intensive and Critical Care, Kidney Sciences, Liver Transplantation, Maxillofacial Surgery, Obstetrics and Gynaecology, Onco Sciences, and more.

Quick check

The five things to look at first. Open one for more.

Compared with its industry

Hospital: 41 companies →

Shalby against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

  • Valuation (P/E)33.7 against a typical 48.6: cheaper than most peers (1st = cheapest).13th of 40
  • Sales growth+11.8% against a typical +21.1% from a year earlier.27th of 34
  • Profit growth+25% against a typical +13% from a year earlier.13th of 31
  • Share price, 3 months−25.4% against a typical −10.9%.33rd of 34
  • Size₹ 1,210.5 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).19th of 36

Credit ratings

Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates

Look closer

Rated A by ICRA
A
DefaultRiskyModerateSafeVery safe
  • ICRA lowered its rating on 27 Jul 2026.
AgencyCurrent ratingOutlookAs of
ICRA[ICRA]AStable27 Jul 2026
Credit rating actions
RatingDetails
27 Jul 2026
▼ Downgrade
[ICRA]A—ICRA₹ 830 Cr.

Board meetings

Results dates and other board meetings. Full calendar

Details
3 Nov 2026UpcomingFinancial Results/Other business mattersTo consider and approve the financial results for the period ended September 30, 2026 and other business matters
12 Aug 2026Financial Results/Other business mattersSHALBY : 12-Aug-2026 : The Company has informed the Exchange that a Board meeting to be held on August 05, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on August 12, 2026, To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters
5 Aug 2026Financial ResultsTo consider and approve the unaudited financial results (standalone and consolidated) for the quarter ended Jun 30, 2026
27 May 2026Financial Results/Dividend/Other business mattersTo consider and approve the audited financial (standalone & consolidated) results for the quarter and year ended March 31, 2026, recommendation of dividend, if any, and other business matters.
11 Feb 2026Financial Results/Other business mattersTo consider and approve the financial results for the period ended December 31, 2025 and other business matters
13 Nov 2025Financial ResultsTo consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2025.
13 Aug 2025Financial ResultsTo consider and approve the financial results for the period ended Jun 30, 2025

Share price

1Y change −49.78%
Volume (shares)Price (₹)
Close price

Financials

Consolidated figures in ₹ crore.

Quarterly results
₹ Cr.Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales238216244279268276265296285272287331
Expenses185174205234235242244255244242258290
Operating Profit534239453334214242302942
OPM %22%20%16%16%12%12%8%14%15%11%10%13%
Other Income5551075574787
Interest34689111191011911
Depreciation121216161716161717181819
Profit before tax433122301412−1231991020
Tax %35%38%26%52%83%124%1,547%66%62%86%−92%47%
Net Profit281916152−3−128711810
EPS in Rs2.551.771.541.450.31−0.17−1.020.830.780.161.71

Growth and returns

Compounded yearly rates over each period.

Compounded Sales Growth
10 Years
15%
5 Years
22%
3 Years
12%
TTM
7%
Compounded Profit Growth
10 Years
−4%
5 Years
−11%
3 Years
−28%
TTM
7,663%
Stock Price CAGR
10 Years
—
5 Years
−4%
3 Years
−11%
TTM
—
Return on Equity
10 Years
5%
5 Years
5%
3 Years
3%
TTM
—

Shareholding

Latest: Jun 2026.

Promoters
74.33%
+0.06 pts in a year
FIIs
4.47%
−0.74 pts in a year
DIIs
0.3%
+0.11 pts in a year
Public
20.26%
+0.61 pts in a year
Others
0.65%
−0.04 pts in a year

P/E and EPS over time

Daily P/E and trailing 12-month EPS. EPS updates with each result.

P/E 33.7xEPS (12 months) ₹ 3.64Median P/E 37.7x
P/E (times)EPS (₹)

Peers

Listed companies in the same business.

Peer comparison
Shalby₹ 121.30₹ 1,210 Cr.33.7x1.2x2%—
Apollo Hospitals Enterprise₹ 7,731.95₹ 1,11,174 Cr.64.9x13.4x22%7.8%
Max Healthcare Institute₹ 817.00₹ 79,519 Cr.71.5x9.9x14.3%17.2%
Fortis Healthcare₹ 720.00₹ 54,357 Cr.67.9x7.3x11.1%11.7%
Aster DM Healthcare₹ 651.00₹ 56,817 Cr.102.6x9.3x9.7%9.2%
Narayana Hrudayalaya₹ 1,667.25₹ 33,862 Cr.48.1x9.1x19.9%10.3%

Management

Vikram Shah
Chairman of the Board, Managing Director
Amit Kumar
Chief Financial Officer
Tushar Dineshchand Shah
Company Secretary, Associate Vice President

Prices are delayed and for information only. Nothing on this page is investment advice.